DENVER, Colo. (247marketnews.com) -- BARDA awarded SCYNEXIS (NASDAQ:SCYX) a contract worth up to approximately $214 million in potential funding puts SCY-247 at the center of a much bigger public-health and biotech narrative: the race to develop new weapons against increasingly drug-resistant fungal infections.
The headline number needs context. The contract’s initial base period provides approximately $18.5 million, supporting development of both oral and intravenous SCY-247 into a Phase 2 trial for invasive candidiasis. The full potential value reaches roughly $214 million only if all contract options are exercised, and the agreement can extend for up to 10 years. The structure is also cost-share, meaning SCYNEXIS remains responsible for part of eligible program costs.
Still, the strategic shift is significant. SCY-247 has already produced positive Phase 1 oral data, while the company completed dosing in its Phase 1 intravenous study earlier this year. SCYNEXIS says the oral formulation was well tolerated and achieved preliminary target exposures, while earlier laboratory work showed activity against difficult-to-treat pathogens including Candida auris and echinocandin-resistant C. glabrata. Those findings remain preliminary; SCY-247 is investigational and has not been approved for marketing.
The BARDA award also arrives as SCYNEXIS is building a second clinical pillar. The company initiated a Phase 1 study of SCY-770 in June for autosomal dominant polycystic kidney disease, with Phase 2 proof-of-concept enrollment targeted for the fourth quarter of 2026. Its August update reported $71.1 million in cash, cash equivalents and investments at June 30 and reiterated a cash runway into 2029.
That makes the BARDA deal more than another development milestone. It potentially gives SCYNEXIS a way to push SCY-247 forward while preserving resources for SCY-770. As CEO David Angulo put it: “Importantly, it strengthens our pipeline by allowing us to advance two programs into Phase 2.”
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.